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1. Introduction 
Considerable research work has been done to im- 
prove insulin preparations in terms of controlled onset 
and duration of action [l-5] . However, despite the 
various types of insulin preparations available for 
therapy, it may still be of some interest to follow new 
ideas in this field. 
Thus, based on Katchalski’s work [6] and our 
own observations with enzymes and other biological 
active peptides covalentLy linked to synthetic polymers 
[7], we prepared a water soluble insulin-polyacrylate 
compound (I-PA). 
2. Methods and materials 
2.1. Polyacrylic anhydride 
(PAA) was prepared from its monomer (acrylic 
anhydride, 10% in water-free benzene) in 60% yield 
as described in [8]. The weight average molecular 
weight of our PAA measured in a light scattering 
photometer (Sofica, PGD 42000) and calculated 
from a Zimm plot was 140,000. For preparation of 
I-PA, PAA was dissolved in water-free dimethyl- 
formamide at a concentration of 33 mg/ml. Since 
prior to solution PAA forms an invisible gel, this 
system has to be shaken overnight. 
2.2. Insulin-polyacrylate (I-PA) 
100 mg bovine insulin (Serva, Feinbiochemica- 
Heidelberg, 23 international units per mg, 0.4% zinc) 
North-Holland Publishing Company - Amsterdam 
was dissolved in 15 ml 0.2 M phosphate buffer, 
pH 7.5, containing 80 mg EDTA (tetra sodium salt) 
at room temp. The solution was cooled in an ice bath 
and under rapid stirring 3 ml of dimethylformamide 
containing 99 mg PAA was added over a period of 
l-2 min. The mixture was stirred for 6 hr at 3’, 
allowed to stand overnight at 8”) and lyophylized. 
The dry material was dissolved in 10 ml Hz 0 and 
submitted to gel chromatography (Sephadex G-100 
fine, 3 X 40 cm, H2 0). 
Fractions containing 10 ml were collected and 
lyophylized. From each fraction a UV-spectrum at 
a standard concentration of 1 mg/mlO.O5 M phos- 
phate buffer was recorded, from which the respective 
insulin content was calculated. This procedure of 
preparation of I-PA was repeated five times with 
essentially the same result. 
2.3. I-PA-(insulin-‘2sI) 
Insulin-125I was prepared according to Greenwood 
and Hunter’s method [9] using 2 mCi sodium iodide- 
“‘1 type IMS 30, from Radiochemical Center, Amers- 
ham. The procedure was slightly modified in the 
following way: a) for iodination 50 Erg insulin (Serva) 
was added, b) after iodination, 0.8 ml phosphate buf- 
fer (0.05 M, pH 7.5) containing 1000 pg insulin (Ser- 
va) was added, c) gel chromatography was carried 
out using a 1.5 X 25 cm Sephadex G-50 column, 
0.05 M phosphate buffer pH 7.5,2 ml fraction was 
determined after appropriate dilution (H2 0) in a 
liquid scintillation spectrometer, Packard TriCarb, 
model 544, using NEN aquasol as scintillation liquid. 
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Fig. 1. Gel chromatogram of I-PA. a) Solid line: 1.8 ml of 
the reaction mixture of I-PA was Sephadexed on GlOO 
tine (1.5 X 40 cm column, H20, for further details see 
Methods and materials). b) Broken line: 1.8 ml of solvent 
containing 1.5 ml 0.2 M phosphate buffer, pH 7.5, 0.3 ml 
dimethylformamide, 10 mg insulin and 8 mg EDTA (tetra- 
sodium salt) was submitted to gel chromatography as de- 
scribed in a. 
The yield of ‘*‘iodine bound to insulin was 90%. The 
insulin containing fractions were pooled and divided 
into two aliquots, which were lyophylized. 
For preparation of I-PA-(insulin-‘*’ I) one aliquot 
was dissolved in 3.2 ml phosphate buffer, 0.1 M, 
pH 7.5, containing 19 mg insulin (Serva) and 12 mg 
EDTA, and, under cooling and rapid stirring, 0.6 ml 
dimethylformamide containing 20 mg PAA was added. 
Isolation and purification procedures were carried 
out as described above for the preparation of unlabel- 
led I-PA. The final product was separated on Sepha- 
dex G-100 fine, 1.5 X 40 cm. Ha0 was taken for 
elution and 3 ml fractions were collected. Each fraction 
was measured for radioactivity as described above. 
According to the data obtained, more than 98% of 
the insulin had reacted with PAA. 
To assure the covalent nature of the binding of 
insulin in I-PA, an aliquot equivalent to 120 pg I-PA- 
(insulin-‘25 I) was taken from the peak fraction of the 
gel chromatogram and 5000 pg non-radioactive 
insulin dissolved in 1 .O ml 0.05 M phosphate buffer 
was added. The solution was allowed to stand over- 
night at 15” and was submitted to gel chromato- 
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Fig. 2. Depression of serum glucose level in rats after sub- 
cutaneous injection of I-PA. Ordinate: serum glucose level 
in percent of initial (normal) concentration. I-PA (solid line) 
contains 20% bound insulin, and the dose corresponds there- 
fore to 1200 fig bound insulin/l000 g rat. 
graphy as described above. The absorbance at 27.5 nm 
and the radioactivity of each fraction was measured. 
2.4. Hypoglycemic effect of I-PA 
The biological activity of I-PA was measured ac- 
cording to the directions for insulin assay issued by 
the United States Pharmacopeia (U.S.P. XVIII, page 
883, Blood-Sugar Method). Female Sprague Dawley 
rats (220-240 g), and female NZW rabbits (230& 
2700 g) were used. 
Serum glucose levels were determined in a Techni- 
kon-Autoanalyzer according to Brown’s method [lo] . 
3. Results and discussion 
As is evident from fig. 1, the reaction system used 
allows almost quantitative binding of insulin to poly 
acrylate. In the control experiment, when insulin was 
submitted to gel chromatography in the presence of 
polyacrylate under exactly the same conditions of 
pH and concentration of buffer and EDTA (as em- 
ployed for I-PA gel chromatography), no insulin 
was found in the polymer peak at the exclusion 
volume (fig. 1). 
Moreover, using I-PA which contained ‘*‘I-labelled 
insulin, no dissociation of the I-PA molecule after 
addition of a hundred-fold excess of nonradioactive 
insulin was observed by gel chromatography. 
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Table 1 
Insulin content of I-PA. 
Fraction 
no. 
Weight 
(mg) 
Absorbance 
at 275 nm 
for 1 mg/ml* 
Insulin 
in fraction 
(%) 
Remarks 
14 6 0.092 10.5 _ 
15 14 0.168 19.3 For biol. test 
16 18 0.250 28.6 _ 
17 (peak) 34 0.358 40.6 For biol. test 
18 (peak) 38 0.372 42.5 - 
19 42 0.312 (35.5) Frac. 19 and 20 
contain phosphate 
from the reaction 
20 42 0.257 (29.0) medium 
For details see Methods and materials. 
* 1140 pg insulin (Serva)/ml 0.05 M phosphate buffer shows an absorbance of 1.00 (1 cm cuvette). 
Therefore, complexes of insulin with polyacrylates, 
as described in [ 111, do not occur in our system, nor 
was aggregation of insulin to high molecular forms 
[ 121 observed under our conditions. Thus in I-PA, 
insulin is covalently attached to polyacrylate, pre- 
sumably by its lysylamino or its N-terminal amino 
groups via amide bonds. In the reaction mixture, 
there are about 24 insulin molecules (72 amino 
groups) per 1 PAA molecule (1100 anhydride groups). 
Thus at the best, only 3.3% of the total carboxylic 
groups in the synthetic polymer are engaged in 
binding of insulin. 
However, the I-PA preparation is not homoge- 
neous in terms of insulin content. The I-PA frac- 
tion with the highest molecular weight contains 
much less insulin than those fractions which are 
close to the weight average molecular weight of the 
product (table 1). 
For biological tests we used I-PA preparations 
containing 20% or 40% insulin (table 1). 
Subcutaneously injected, I-PA lowers the serum 
glucose level of rats in a pronounced way (fig. 2). 
Taking into account that the dose applied contains 
20% bound insulin, one finds that about 10 times as 
much bound insulin is needed to evoke the same onset 
in glucose depression as one observes with free in- 
sulin of the fast acting type. However, while free 
insulin is rapidly inactivated (fig. 2), I-PA remains 
fully active for the whole period of observation 
(5 hr). 
Essentially the same findings were obtained with 
rabbits, where the action of subcutaneously injected 
I-PA persisted for at least 12 hr, when a dose of 
1000 pg I-PA per 1000 g rabbit corresponding to 
200 @g bound insulin was administered. 
Upon intraveneous application the hypoglycemic 
effect of I-PA is comparable to “Actrapid” insulin 
(Novo) in terms of rapid onset. With respect to its 
insulin content, intraveneous I-PA is about 6 times 
less active than free insulin in the initial phase, how- 
ever, it is only 3 times less active as far as its overali 
efficiency is concerned. 
From all these observations, the following con- 
clusions can be drawn: a) due to its solubility and 
due to its polymeric nature subcutaneously adminis- 
tered I-PA is released into the bloodstream in a rather 
constant way over an extended period, thus repre- 
senting an insulin preparation of the long acting type 
with a rapid onset, b) the covalent binding to the 
polyanion does not prevent insulin to be inactivated, 
presumably in the same way as insulin is degraded 
in the organism [ 13- 161, however some delay in in- 
activation is observed. According to Merigan’s findings 
with synthetic polyanions of the maleic acid-divinyl- 
ether type [ 171, I-PA is likely to be deposited and 
eventually its insulin moiety catabolized in the cells 
of the reticula-endothelial system [ 161. 
With respect to Cuatrecasas’ findings of biological 
activity of insulin bound to agarose particles [20] and 
our own data about the rapid onset of subcutaneously 
injected I-PA, it appears to be more likely that the 
whole, intact I-PA molecule is biologically active. 
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It is scarcely conceivable that there is an enzymatic 
in viva mechanism which would split specifically the 
amide bonds between insulin and PAA, and would 
release the intact insulin molecule, and even if so, 
such a mechanism would have to be more effective 
or faster than the mechanism of insulin degradation 
which is unlikely [ 13- 161. 
This concept is also supported by recent findings 
of Cuatrecasas who demonstrated that the signifi- 
cant primary event of its biological action involves 
an interaction of the intact insulin molecule with a 
highly specific receptor located in the cell membrane, 
while only insignificant amounts of insulin are found 
in other cell compartments [20]. Since I-PA, with 
its negative charges and its high molecular weight, 
should penetrate into cells much slower than insulin, 
the rapid onset of glucose depression upon intra- 
veneous injection of I-PA can be interpreted in 
terms of a direct interaction of I-PA with Cuatre- 
casas receptor site in the cell membrane. 
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